In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK

Hopkins KL, et al. International Journal of Antimicrobial Agents. 2014.

Review article: Rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers' diarrhoea

Layer P, et al. Alimentary Pharmacology & Therapeutics. 2010.

Travelers' preferences for the treatment and prevention of acute diarrhea

Ericsson CD, et al. Journal of Travel Medicine. 2009.

A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy

Trehan I, et al. The American Journal of Gastroenterology. 2009.

Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based study

Meraz IM, et al. Journal of Travel Medicine. 2008.

A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea

Taylor DN, et al. American Society of Tropical Medicine and Hygiene. 2006.

Introduction: diarrhea at the summit

Shlim DR. Clinical Infectious Diseases [Supplement]. 2005.

Epidemiology of traveler’s diarrhea

Steffen R. Clinical Infectious Diseases [Supplement]. 2005.

Traveler’s diarrhea in the pediatric population: etiology and impact

Mackel S. Clinical Infectious Diseases [Supplement]. 2005.

Prophylactic antimicrobials for traveler’s diarrhea: an early history

Sack RB. Clinical Infectious Diseases [Supplement]. 2005.

Poorly absorbed antibiotics for the treatment of traveler’s diarrhea

Taylor DN. Clinical Infectious Diseases [Supplement]. 2005.

Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy

Infante RM, et al. Clinical Gastroenterology and Hepatology. 2004.

Therapy of travelers' diarrhea with rifaximin on various continents

Steffen R, et al. The American Journal of Gastroenterology. 2003.

Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world

Adachi JA, et al. Clinical Infectious Diseases. 2001.

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

DuPont HL, et al. Clinical Infectious Diseases. 2001.

In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea

Sierra JM, et al. Antimicrobial Agents and Chemotherapy. 2001.

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea

DuPont HL, et al. Digestion. 1998.